“…Hence, the Nrf2‐ARE pathway is considered a high‐value therapeutic target (de Vries et al, 2008; Johnson and Johnson, 2015; van Muiswinkel and Kuiperij, 2005). It is preferentially activated in astrocytes while neurons largely depend on astrocytes for the antioxidant defense (Kraft, Johnson, & Johnson, 2004; Lee, Calkins, Chan, Kan, & Johnson, 2003; Shih et al, 2003). Therefore, unsurprisingly, many studies report that activation of the Nrf2 pathway in astrocytes is neuroprotective (Calkins, Vargas, Johnson, & Johnson, 2010; Chen et al, 2009; Gan, Vargas, Johnson, & Johnson, 2012; Vargas, Johnson, Sirkis, Messing, & Johnson, 2008).…”